Developer docs
API playgroundTry for free, no card

Search company profiles

Inquis Medical

Full company profile

uuid0000eg7

Namestring
Inquis Medical
Legal namestring
Inquis Medical, Inc.
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Inquis Medical is a privately held medical device company founded in 2020 and headquartered in Menlo Park, California, focused on mechanical thrombectomy for venous thromboembolic disease, with an initial emphasis on pulmonary embolism (PE). The company has developed the AVENTUS Precision Thrombectomy System, an integrated single-catheter platform that combines directional aspiration with a proprietary TrueClot tissue-sensing capability designed to differentiate blood, clot, and vessel wall in real time during aspiration. The platform also incorporates an in-line AVENTUS Clot Management System that filters and reinfuses aspirated blood to minimize blood loss, and a complementary AVENTUS Introducer Sheath with adaptive seal technology.

The company sells capital equipment and associated consumables directly to U.S. hospitals and academic medical centers, targeting interventional cardiologists, interventional radiologists, and vascular surgeons who treat PE and deep vein thrombosis. Following FDA 510(k) clearance for the peripheral indication in 2024 and for pulmonary embolism in June 2025, Inquis Medical transitioned to a commercial-stage organization and launched national rollout supported by a $75 million Series C financing closed in January 2026. The AVENTUS IDE pivotal trial enrolled 130 patients across 22 U.S. sites and reported zero device-related major adverse events, a 27% reduction in RV/LV ratio, and a 35.9% reduction in clot burden, providing the primary commercial evidence base.

The company's go-to-market is enterprise field sales to hospital systems, complemented by peer-to-peer physician education, presence at interventional cardiology and radiology conferences (including SCAI), and published clinical evidence in JSCAI. Inquis Medical operates in a competitive segment alongside larger incumbents such as Inari Medical, Penumbra, and BD Peripheral Intervention, and competes on the basis of an integrated system that eliminates multiple catheter exchanges, reduces blood loss to under 50 mL on average, and removes the need for capital equipment outlays. As of early 2026 the company had raised approximately $115 million in total equity financing and was actively scaling its sales force and physician-training infrastructure.

Short descriptiontext

Inquis Medical develops the AVENTUS Thrombectomy System, an integrated single-catheter mechanical thrombectomy platform with proprietary TrueClot tissue-sensing and autologous blood reinfusion, sold to U.S. hospitals and interventional cardiologists and radiologists for treatment of pulmonary embolism and venous thromboembolism.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMenlo Park, United States
HQ citystring
Menlo Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
mechanical thrombectomy devices, pulmonary embolism treatment, venous thromboembolism therapy, catheter-based thrombectomy, interventional vascular devices
Industry1 code
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Mechanical Thrombectomy Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1AVENTUS Thrombectomy System Sales
TypeHardware Sales
Description

Revenue is generated through the sale of the AVENTUS Thrombectomy System and related consumables (introducer sheaths, blood filtration components) to hospitals and healthcare providers. The system is sold as a capital device with associated procedural consumables.

inquismedical.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1AVENTUS Thrombectomy System
Description

Next-generation mechanical thrombectomy platform with proprietary TrueClot tissue-sensing technology for treatment of pulmonary embolism and peripheral vascular conditions.

inquismedical.com
Core offering1 text field

Inquis Medical develops and commercializes the AVENTUS Thrombectomy System, a next-generation mechanical thrombectomy platform for treating venous thromboembolic disease including pulmonary embolism (PE) and deep vein thrombosis (DVT). The system combines a 24-F aspiration catheter with proprietary TrueClot tissue-sensing technology, integrated directional aspiration, and the AVENTUS Clot Management System for autologous blood reinfusion. The company sells the device and associated consumables (introducer sheaths, blood filtration components) to U.S. hospitals and interventional physicians.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Zero device-related major adverse events (MAEs) within 48 hours and through 30 days across 130 patients in pivotal trial
+5 more records
Product overview1 text field

Inquis Medical offers the AVENTUS Precision Thrombectomy System as its core product platform for treating venous thromboembolic disease. The system consists of the AVENTUS Thrombectomy System (main aspiration catheter with TrueClot™ sensing technology), the AVENTUS Clot Management System (blood filtration and reinfusion module), and the AVENTUS Introducer Sheath (access device with adaptive seal). These products work together as an integrated platform enabling precision clot removal with real-time tissue sensing and autologous blood reinfusion for pulmonary embolism and peripheral vascular procedures.

Product and service3 records
1AVENTUS Thrombectomy System
CategoryMechanical Thrombectomy Catheter System
Description

Next-generation mechanical thrombectomy platform for treating venous thromboembolic disease including pulmonary embolism (PE) and deep vein thrombosis (DVT). Features proprietary TrueClot tissue-sensing technology for real-time differentiation between blood, clot, and vessel wall, integrated directional aspiration, and 24-F catheter design with no capital equipment required. Sold to U.S. hospitals and interventional cardiologists/radiologists.

2AVENTUS Clot Management System
CategoryProcedural Consumable / Blood Management Module
Description

Blood filtration and reinfusion system used with the AVENTUS Thrombectomy System to enable autologous blood transfusion. Filters aspirated blood and returns it to the patient without syringe disconnection, reducing blood loss to under 50 mL mean per patient and eliminating transfusion requirements.

3AVENTUS Introducer Sheath
CategoryVascular Access Device / Procedural Consumable
Description

Introducer sheath with adaptive seal technology featuring single-handed control using one button and an iris valve that delivers consistent sealing across all device sizes. Compatible with the AVENTUS Thrombectomy System for smooth and effortless device advancement during PE and peripheral vascular procedures.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Merit Medical offers a portfolio of vascular intervention, drainage, and thrombectomy-related devices sold to interventional radiology and cardiology customers, making it a broad incumbent competing for hospital share of wallet.

TypeOthers
Description

Stryker acquired Inquis co-founder Vahid Saadat's prior company Arrinex, demonstrating a known acquisition appetite in medtech. While Stryker's current portfolio is not a direct PE thrombectomy competitor, it represents a credible strategic acquirer for Inquis.

TypeDirect peer
Description

Penumbra's Indigo aspiration system with Lightning intelligent aspiration is a leading catheter-based thrombectomy platform for PE and venous thromboembolism, directly overlapping with AVENTUS in indication, mechanism, and customer base.

TypeBroad incumbent
Description

BD's Peripheral Intervention business includes the Rotarex rotational thrombectomy catheter and broader venous/vascular portfolio. Inquis's CCO Matt Fermanich previously led BD Peripheral Intervention, illustrating direct competitive overlap and incumbency.

TypeOthers
Description

Edwards Lifesciences is a major cardiovascular medtech incumbent serving interventional cardiology and cardiac surgery customers; not a direct thrombectomy competitor but a comparable cardiovascular hospital-channel peer and potential strategic acquirer.

TypeDirect peer
Description

Inari Medical's FlowTriever and ClotTriever systems are the leading mechanical thrombectomy platforms for pulmonary embolism and DVT — the most direct competitor to AVENTUS in target indication, customer (interventional cardiology/radiology), and procedural use case.

TypeBroad incumbent
Description

Boston Scientific is a broad interventional medtech incumbent with a peripheral intervention portfolio (including AngioJet and acquired Devoro Medical rotational thrombectomy assets) and large hospital sales force targeting the same interventional cardiology and radiology accounts.

TypeDirect peer
Description

AngioDynamics markets the alphaVac system for mechanical thrombectomy in PE, directly competing with AVENTUS in indication, mechanism of action, and target hospital accounts for venous thromboembolism.

TypeBroad incumbent
Description

Teleflex offers interventional vascular access and thrombectomy-adjacent products to the same hospital-based interventionalists; a broad incumbent whose portfolio competes for the same procedural budgets.

TypeBroad incumbent
Description

J&J markets the AngioVac venous thrombectomy system and a broad interventional cardiology/radiology portfolio, serving the same hospital accounts and competing in PE and venous thromboembolism.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Inquis Medical

Mechanical Thrombectomy Devicesinquismedical.com

Inquis Medical develops the AVENTUS Thrombectomy System, an integrated single-catheter mechanical thrombectomy platform with proprietary TrueClot tissue-sensing and autologous blood reinfusion, sold to U.S. hospitals and interventional cardiologists and radiologists for treatment of pulmonary embolism and venous thromboembolism.

What Inquis Medical does

Inquis Medical is a privately held medical device company founded in 2020 and headquartered in Menlo Park, California, focused on mechanical thrombectomy for venous thromboembolic disease, with an initial emphasis on pulmonary embolism (PE). The company has developed the AVENTUS Precision Thrombectomy System, an integrated single-catheter platform that combines directional aspiration with a proprietary TrueClot tissue-sensing capability designed to differentiate blood, clot, and vessel wall in real time during aspiration. The platform also incorporates an in-line AVENTUS Clot Management System that filters and reinfuses aspirated blood to minimize blood loss, and a complementary AVENTUS Introducer Sheath with adaptive seal technology.

The company sells capital equipment and associated consumables directly to U.S. hospitals and academic medical centers, targeting interventional cardiologists, interventional radiologists, and vascular surgeons who treat PE and deep vein thrombosis. Following FDA 510(k) clearance for the peripheral indication in 2024 and for pulmonary embolism in June 2025, Inquis Medical transitioned to a commercial-stage organization and launched national rollout supported by a $75 million Series C financing closed in January 2026. The AVENTUS IDE pivotal trial enrolled 130 patients across 22 U.S. sites and reported zero device-related major adverse events, a 27% reduction in RV/LV ratio, and a 35.9% reduction in clot burden, providing the primary commercial evidence base.

The company's go-to-market is enterprise field sales to hospital systems, complemented by peer-to-peer physician education, presence at interventional cardiology and radiology conferences (including SCAI), and published clinical evidence in JSCAI. Inquis Medical operates in a competitive segment alongside larger incumbents such as Inari Medical, Penumbra, and BD Peripheral Intervention, and competes on the basis of an integrated system that eliminates multiple catheter exchanges, reduces blood loss to under 50 mL on average, and removes the need for capital equipment outlays. As of early 2026 the company had raised approximately $115 million in total equity financing and was actively scaling its sales force and physician-training infrastructure.

Inquis Medical firmographics

Firmographics
Name
Inquis Medical
Legal name
Inquis Medical, Inc.
Website
https://inquismedical.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
51–100 employees
Short description
Inquis Medical develops the AVENTUS Thrombectomy System, an integrated single-catheter mechanical thrombectomy platform with proprietary TrueClot tissue-sensing and autologous blood reinfusion, sold to U.S. hospitals and interventional cardiologists and radiologists for treatment of pulmonary embolism and venous thromboembolism.
Ownership category
akta.pro rank

Inquis Medical industry classification

Industry
Product category
Mechanical Thrombectomy Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Mechanical thrombectomy devices
  • Pulmonary embolism treatment
  • Venous thromboembolism therapy
  • Catheter-based thrombectomy
  • Interventional vascular devices

Where Inquis Medical is headquartered

Location

Headquarters

HQ city
Menlo Park
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Inquis Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. AVENTUS Thrombectomy System Sales: Revenue is generated through the sale of the AVENTUS Thrombectomy System and related consumables (introducer sheaths, blood filtration components) to hospitals and healthcare providers. The system is sold as a capital device with associated procedural consumables.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Inquis Medical product offering

Product offering

Core offering

Inquis Medical develops and commercializes the AVENTUS Thrombectomy System, a next-generation mechanical thrombectomy platform for treating venous thromboembolic disease including pulmonary embolism (PE) and deep vein thrombosis (DVT). The system combines a 24-F aspiration catheter with proprietary TrueClot tissue-sensing technology, integrated directional aspiration, and the AVENTUS Clot Management System for autologous blood reinfusion. The company sells the device and associated consumables (introducer sheaths, blood filtration components) to U.S. hospitals and interventional physicians.

Product overview

Inquis Medical offers the AVENTUS Precision Thrombectomy System as its core product platform for treating venous thromboembolic disease. The system consists of the AVENTUS Thrombectomy System (main aspiration catheter with TrueClot™ sensing technology), the AVENTUS Clot Management System (blood filtration and reinfusion module), and the AVENTUS Introducer Sheath (access device with adaptive seal). These products work together as an integrated platform enabling precision clot removal with real-time tissue sensing and autologous blood reinfusion for pulmonary embolism and peripheral vascular procedures.

Differentiator

Problem solved

Functional benefit

Brands

  • AVENTUS Thrombectomy System: Next-generation mechanical thrombectomy platform with proprietary TrueClot tissue-sensing technology for treatment of pulmonary embolism and peripheral vascular conditions.

Products and services

  • AVENTUS Thrombectomy System Next-generation mechanical thrombectomy platform for treating venous thromboembolic disease including pulmonary embolism (PE) and deep vein thrombosis (DVT). Features proprietary TrueClot tissue-sensing technology for real-time differentiation between blood, clot, and vessel wall, integrated directional aspiration, and 24-F catheter design with no capital equipment required. Sold to U.S. hospitals and interventional cardiologists/radiologists.
  • AVENTUS Clot Management System Blood filtration and reinfusion system used with the AVENTUS Thrombectomy System to enable autologous blood transfusion. Filters aspirated blood and returns it to the patient without syringe disconnection, reducing blood loss to under 50 mL mean per patient and eliminating transfusion requirements.
  • AVENTUS Introducer Sheath Introducer sheath with adaptive seal technology featuring single-handed control using one button and an iris valve that delivers consistent sealing across all device sizes. Compatible with the AVENTUS Thrombectomy System for smooth and effortless device advancement during PE and peripheral vascular procedures.

Quantifiable outcome

  • Zero device-related major adverse events (MAEs) within 48 hours and through 30 days across 130 patients in pivotal trial
  • +5 more outcomes

Companies that use Inquis Medical

Customer profile

Named customers3 records

Segments1 record

Ideal customer profiles1 record

Inquis Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Inquis Medical partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Inquis Medical competitors and assessment

Company assessment

Broad incumbents

  • Merit Medical Systems: Merit Medical offers a portfolio of vascular intervention, drainage, and thrombectomy-related devices sold to interventional radiology and cardiology customers, making it a broad incumbent competing for hospital share of wallet.
  • Becton Dickinson (BD): BD's Peripheral Intervention business includes the Rotarex rotational thrombectomy catheter and broader venous/vascular portfolio. Inquis's CCO Matt Fermanich previously led BD Peripheral Intervention, illustrating direct competitive overlap and incumbency.
  • Boston Scientific: Boston Scientific is a broad interventional medtech incumbent with a peripheral intervention portfolio (including AngioJet and acquired Devoro Medical rotational thrombectomy assets) and large hospital sales force targeting the same interventional cardiology and radiology accounts.
  • Teleflex: Teleflex offers interventional vascular access and thrombectomy-adjacent products to the same hospital-based interventionalists; a broad incumbent whose portfolio competes for the same procedural budgets.
  • Johnson & Johnson (Biosense Webster / J&J MedTech): J&J markets the AngioVac venous thrombectomy system and a broad interventional cardiology/radiology portfolio, serving the same hospital accounts and competing in PE and venous thromboembolism.

Others

  • Stryker: Stryker acquired Inquis co-founder Vahid Saadat's prior company Arrinex, demonstrating a known acquisition appetite in medtech. While Stryker's current portfolio is not a direct PE thrombectomy competitor, it represents a credible strategic acquirer for Inquis.
  • Edwards Lifesciences: Edwards Lifesciences is a major cardiovascular medtech incumbent serving interventional cardiology and cardiac surgery customers; not a direct thrombectomy competitor but a comparable cardiovascular hospital-channel peer and potential strategic acquirer.

Direct peers

  • Penumbra: Penumbra's Indigo aspiration system with Lightning intelligent aspiration is a leading catheter-based thrombectomy platform for PE and venous thromboembolism, directly overlapping with AVENTUS in indication, mechanism, and customer base.
  • Inari Medical: Inari Medical's FlowTriever and ClotTriever systems are the leading mechanical thrombectomy platforms for pulmonary embolism and DVT — the most direct competitor to AVENTUS in target indication, customer (interventional cardiology/radiology), and procedural use case.
  • AngioDynamics: AngioDynamics markets the alphaVac system for mechanical thrombectomy in PE, directly competing with AVENTUS in indication, mechanism of action, and target hospital accounts for venous thromboembolism.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Inquis Medical social profiles

Digital presence

Inquis Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Inquis Medical leadership team

Management profile

Number of profiles

Profiles16 records

Inquis Medical funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Inquis Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inquis Medical

What does Inquis Medical do?

Inquis Medical develops and commercializes the AVENTUS Thrombectomy System, a next-generation mechanical thrombectomy platform for treating venous thromboembolic disease including pulmonary embolism (PE) and deep vein thrombosis (DVT). The system combines a 24-F aspiration catheter with proprietary TrueClot tissue-sensing technology, integrated directional aspiration, and the AVENTUS Clot Management System for autologous blood reinfusion. The company sells the device and associated consumables (introducer sheaths, blood filtration components) to U.S. hospitals and interventional physicians.

Is Inquis Medical a public or private company?

Inquis Medical is a private company. It is classified as venture growth investor backed and is currently operating.

When was Inquis Medical founded?

Inquis Medical was founded in 2020. It employs 51 to 100 people.

Where is Inquis Medical based?

Inquis Medical is headquartered in Menlo Park, United States, in the North America region.

How does Inquis Medical make money?

One revenue line is on record: AVENTUS Thrombectomy System Sales.

Who are Inquis Medical's main competitors?

Broad incumbents on record are Merit Medical Systems, Becton Dickinson (BD), Boston Scientific, Teleflex and Johnson & Johnson (Biosense Webster / J&J MedTech). Others are Stryker and Edwards Lifesciences. Direct peers are Penumbra, Inari Medical and AngioDynamics.

Does Inquis Medical have an API?

No public API is recorded for Inquis Medical.

What industry is Inquis Medical in?

Inquis Medical's product category is Mechanical Thrombectomy Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American City Business JournalsInquis Medical raises $75 million for next round of medical-device growthInquis Medical has raised $75 million in funding to support its next round of growth for medical devices. The article highlights customer feedback regarding the company's products as part of this development.FinSMEsInquis Medical Raises $75M in Series C FundingInquis Medical raised $75 million in Series C funding from an undisclosed strategic investor to accelerate nationwide commercial expansion of its AVENTUS Thrombectomy System and expand its sales and physician-training infrastructure. The Menlo Park-based medical device company, which achieved expanded regulatory clearance for pulmonary embolism and transitioned to a commercial-stage organization in 2025, previously raised a $40 million Series B led by Marshall Wace in August 2024.MassDeviceInquis Medical raises $75M Series C to support thrombectomy systemInquis Medical, a Menlo Park, California–based medical device company, closed a $75 million Series C financing round from an undisclosed strategic investor to accelerate nationwide commercial expansion of its Aventus thrombectomy system and advance its next-generation product pipeline. The Aventus system, which provides real-time tissue-sensing technology during procedures, received FDA 510(k) clearance for peripheral indications in 2024 and FDA clearance for pulmonary embolism treatment in June 2025. The company plans to use the proceeds to expand its sales and physician-training infrastructure and grow its clinical evidence base.BioSpaceInquis Medical Announces $75 Million Series C Financing to Scale Commercial Adoption of its AVENTUS Thrombectomy SystemInquis Medical, a privately held medical technology company based in Menlo Park, California, has closed a $75 million Series C financing round led by an undisclosed strategic investor. The company will use the proceeds to accelerate nationwide commercial expansion of its AVENTUS Thrombectomy System and advance its next-generation product pipeline, following a transformative 2025 that saw it transition into a commercial-stage organization with expanded regulatory clearances for pulmonary embolism and published pivotal trial data in JSCAI.Pulse 2.0Inquis Medical: $75 Million Series C Raised To Expand AVENTUS Thrombectomy Commercial RolloutInquis Medical closed a $75 million Series C to expand its AVENTUS thrombectomy system nationwide. The company cited pivotal clinical data showing significant thrombus removal with minimal blood loss in 130 intermediate-risk PE patients. Funds will support commercial expansion and clinical evidence.Business Wire BlogInquis Medical Announces $75 Million Series C Financing to Scale Commercial Adoption of its AVENTUS Thrombectomy SystemInquis Medical, a privately held medical technology company based in Menlo Park, California, announced the closing of a $75 million Series C financing round from an undisclosed strategic investor to accelerate nationwide commercial expansion of its AVENTUS Thrombectomy System. The funding follows a transformative 2025 in which the company received expanded regulatory clearance for pulmonary embolism treatment and published pivotal trial data showing significant thrombus removal with no device-related adverse events in 130 patients. With this capital infusion, Inquis Medical plans to expand its sales and physician-training infrastructure while advancing its next-generation product pipeline for venous thromboembolic disease treatment.GlobeNewswireInquis Medical’s AVENTUS Thrombectomy System Receives FDA 510(k) Clearance for Treatment of Pulmonary EmbolismInquis Medical's AVENTUS Thrombectomy System received FDA 510(k) clearance for treating pulmonary embolism, expanding its indication. The system includes tissue-sensing technology and a clot management system for blood reinfusion. The clearance follows the AVENTUS Pivotal Trial, which showed safety and rapid improvement in right heart strain.GlobeNewswireTrial Finds Inquis Medical’s AVENTUS Thrombectomy System Safe and Effective for Patients with Pulmonary EmbolismInquis Medical announced AVENTUS trial results at the 2025 SCAI Scientific Sessions, showing the thrombectomy system is safe and effective for acute intermediate-risk pulmonary embolism. The trial enrolled 130 patients across 22 U.S. sites, with zero device-related major adverse events and a mean 0.47 reduction in RV/LV ratio. The company plans to make the system widely available.GlobeNewswireInquis Medical Completes Enrollment in U.S. Pivotal IDE Trial of the Aventus Thrombectomy System Designed to Treat Patients with Pulmonary EmbolismInquis Medical completed enrollment in its AVENTUS Clinical Trial, a pivotal IDE trial evaluating the Aventus Thrombectomy System for pulmonary embolism. The multicenter, single-arm trial enrolled 130 patients with intermediate-risk PE across over 20 U.S. sites. The company is now one step closer to demonstrating the system's potential to revolutionize PE treatment.Pulse 2.0Inquis Medical: Thrombectomy Systems Focused Company Raises $40 Million (Series B)Inquis Medical closed a $40 million Series B round led by Marshall Wace, with participation from existing investors. The funding supports its Aventus thrombectomy system, which received FDA 510(k) clearance, and aims to complete a pivotal IDE trial and launch in 2025.